Dual Phase 3 Uveitis Win Impresses but Safety Gap Blocks Approval Certainty

Roivant Subsidiary Reports Positive Phase 3 Results for Brepocitinib

Priovant Therapeutics, a subsidiary of Roivant, announced positive results from two Phase 3 studies (Clarity-1 and Clarity-2) for its anti-inflammatory medicine, brepocitinib, in non-infectious uveitis. Patients treated with brepocitinib achieved a median of over 48 weeks before "treatment failure," significantly outperforming the 12 weeks seen in the placebo group. Additionally, these patients went 40 weeks without requiring immunosuppressive steroids, setting a new benchmark for the disease. The drug also met all secondary endpoints, including the resolution of macular edema. Priovant plans to submit a supplemental application for this new indication in the first half of next year, building on its existing FDA approval for brepocitinib (Lisraya) in dermatomyositis.

• Brepocitinib demonstrated superior efficacy in Phase 3 Clarity-1 and Clarity-2 trials for non-infectious uveitis, with patients experiencing a median of over 48 weeks to treatment failure compared to 12 weeks for placebo. This outcome, along with 40 weeks without immunosuppressive steroids, suggests a potential new standard of care for the debilitating eye condition.
• The successful Phase 3 results for brepocitinib in non-infectious uveitis reinforce its potential as a "best-in-disease" medicine, expanding its utility beyond its current FDA approval for dermatomyositis. Analysts project non-infectious uveitis alone could represent a $5 billion peak sales indication, validating Roivant's strategy of developing multi-indication franchises in rare and specialty markets.
• Priovant Therapeutics, formed through a partnership between Roivant and Pfizer, is preparing to submit a supplemental New Drug Application for brepocitinib in non-infectious uveitis in the first half of the upcoming year. This follows successful Phase 2 testing in 2024 and underscores Roivant's model of advancing later-stage assets through specialized "Vant" units.

Addressing Unmet Needs in Non-infectious Uveitis Treatment

Current treatment of non-infectious uveitis (NIU) is constrained by variable response to biologics, substantial ocular and systemic toxicities, and recurrent disease with incomplete long-term remission. Even with anti-TNF-alpha therapy, local corticosteroids, and steroid-sparing immunosuppressants, vision-threatening complications and treatment failure remain common.

• Suboptimal response and immunogenicity to TNF-alpha inhibitors: Patients with suboptimal response to every two-week dosing of adalimumab may suffer from recurrent inflammation and vision loss, with 31.2% (n=10) of 32 patients found to have neutralizing drug antibodies defined as serum drug levels less than or equal to 6 mcg/mL with anti-adalimumab antibodies present on reflex testing. Formation of anti-ADA antibodies was associated with low serum ADA trough levels (SATL) and poor treatment response, with transient anti-ADA antibodies linked to a higher risk of treatment failure, highlighting benefits of combined therapy with ADA and other immunosuppressants compared with ADA monotherapy.

• Steroid-related ocular hypertension, glaucoma, and cataract: The OHT rate after 0.18 mg fluocinolone acetonide implant (FAi, Yutiq) was 10.5%, with elevated IOP ≥30 mmHg in 5.82% and IOP >12 mmHg from baseline in 7.3%, while dexamethasone 0.7 mg intravitreal implant (Ozurdex) monotherapy increased mean IOP from 18.20 to 23.20 mmHg at 1 month, with three patients developing IOP >30 mmHg and three eyes developing cataract. Combination of intravitreal anti-VEGF plus intravitreal steroids showed no meaningful clinical difference in change in best corrected visual acuity (BCVA) versus anti-VEGF monotherapy but greater risk of raised IOP (Peto odds ratio (OR) 8.13, 95% CI 4.67 to 14.16) and development of cataract (Peto OR 7.49, 95% CI 2.87 to 19.60). Patients with non-infectious uveitis had a nearly tenfold increased risk of developing glaucoma compared to controls (HR, 9.63; 95% CI, 7.75-11.95), highest during the first follow-up year (HR, 33.78; 95% CI, 19.02-59.90), with panuveitis associated with the greatest risk (HR, 50.49; 95% CI, 22.36-113.00).

• Time-limited durability and recurrent macular edema: Uveitic macular edema (UME) is the most common sight-threatening complication in uveitis with usually recurrent nature and refractory to conventional treatment. Dexamethasone implant monotherapy showed Kaplan-Meier estimated first-implant treatment success at 74% between 3 and 6 months and 42% after 9 months, with five eyes receiving a second implant generally around 6 months after the first for persistent or recurrent CME, and 31.3% of FAi-treated eyes requiring supplemental corticosteroid injections.

• Incomplete remission and systemic toxicity of steroid-sparing agents: Cyclosporine therapy resulted in visual acuity improvement or stabilisation in approximately 79% of patients (event rate=0.879; 95% CI 0.832 to 0.914) and control of intraocular inflammation in approximately 77% (event rate=0.767; 95% CI 0.705 to 0.818), but complete disease remission was achieved in only about 43% (event rate=0.43; 95% CI 0.39 to 0.48). Adverse effects were common, with fatigue affecting approximately 65% of patients, nephrotoxicity in 57%, and hypertension in about 21%, requiring regular renal monitoring and periodic blood pressure assessment.

• Relapse risk and difficult-to-control populations: COVID-19 infection increases the rate of uveitis relapse, with relapse rate higher (28.8%, n=288) in those with COVID-19 infection than in patients without infection (14.8%, n=61), with long disease duration as a risk factor. Inflammation is difficult to control in juvenile idiopathic arthritis-associated uveitis (JIA-U) even with appropriate treatment, with risk of blindness after transition linked to delay in commencement of treatment and failure to provide transitional care.

Brepocitinib's Clarity Trials: Setting a New Standard

Long-term adalimumab data in noninfectious intermediate, posterior, or panuveitis come from the VISUAL III phase 3 extension study and a Japanese nationwide post-marketing surveillance. Both evaluated safety alongside quiescence and ocular inflammatory measures with corticosteroid-sparing effects.

Brepocitinib's Potential to Redefine Non-infectious Uveitis Care

In published studies of non-infectious intermediate, posterior, or panuveitis, oral methotrexate 25 mg weekly achieved treatment success in 69% of patients compared with 47% with mycophenolate mofetil 1 g twice daily (P = 0.09), with treatment defined by ≤0.5+ anterior chamber cells, ≤0.5+ vitreous cells, ≤0.5+ vitreous haze and no active retinal/choroidal lesions in both eyes, ≤10 mg of prednisone and ≤2 drops of prednisolone acetate 1% a day, and no declaration of treatment failure because of intolerability or safety at 5 and 6 months. Treatment failure from adverse events or tolerability was not different by treatment arm (P = 0.99), and there were no differences in time to corticosteroid-sparing control of inflammation (P = 0.44), change in best spectacle-corrected visual acuity (P = 0.68), or resolution of macular edema (P = 0.31). In network synthesis, adalimumab plus corticosteroids was associated with significant reduction in hazard of treatment failure over time (HR 0.51, 95% CrI: 0.24-0.95) compared with corticosteroids monotherapy, with an estimated overall treatment failure rate at month 6 of 37.6%.

Intravitreal sirolimus 440 μg improved ocular inflammation compared with the 44 μg dose in the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program, with VH of 0 in 21.2% vs. 13.5% (P = 0.038) and VH of 0 or 0.5+ in 50.0% vs. 40.4% (P = 0.049) at month 5 without use of rescue therapy. Best-corrected visual acuity was stable (absolute change <5 ETDRS letters) or improved >5 letters in 80.1% and 80.2% of patients in the 440-μg and 44-μg groups, respectively, and corticosteroids were tapered successfully in 69.6% and 68.8% of patients, with VH of 0 or 0.5+ achieved by 43.5% and 28.1% among tapered patients. In SAVE-2, vitreous haze decreased by ≥2 steps in 63.6% and 50% of patients in the 440 μg monthly and 880 μg every 2 months groups at month 6 (p=0.695), with mean change in best-corrected visual acuity of +3.66 and -2.91 ETDRS letters and mean change in foveal thickness of -89.42µm and +81.5µm among subjects with macular edema at baseline (n=13). Intravitreal adalimumab 1.5 mg every 4 weeks was non-inferior to subcutaneous adalimumab 40 mg every 2 weeks (after 80 mg loading) for change in anterior chamber cell grade (-0.33 [-0.79 to 0.38], p = 0.440) and vitreous haze grade (-0.34 [-1.15 to 0.47], p = 0.490) at 26 weeks against a noninferiority margin of +0.5 grade, with no significant differences in changes in BCVA (p = 0.594), CRT (p = 0.607), FA score (p = 0.318), and oral prednisone dose (p = 0.881), and 21 non-serious systemic adverse events with subcutaneous versus 5 with intravitreal administration.

Corticosteroid implants decreased the risk of uveitis recurrence by 60% versus sham at 6 months (relative risk [RR] 0.40, 95% confidence interval [CI] 0.30 to 0.54; 2 trials, 282 participants) and by 54% versus standard-of-care therapy at 24 months (RR 0.46, 95% CI 0.35 to 0.60; 2 trials, 619 eyes), with mean difference in BCVA of 0.22 logMAR (95% CI 0.13 to 0.31; 1 trial, 153 participants) versus sham and 0.05 logMAR (95% CI -0.02 to 0.12; 2 trials, 619 eyes) versus standard of care. Compared with sham, implants increased elevated intraocular pressure ([IOP] RR 2.81, 95% CI 1.42 to 5.56; 2 trials, 282 participants) and need for IOP-lowering eyedrops (RR 1.85, 95% CI 1.05 to 3.25), while 0.59 mg fluocinolone acetonide implant versus standard of care increased cataract progression (RR 2.71, 95% CI 2.06 to 3.56), need for surgery (RR 2.98, 95% CI 2.33 to 3.79), elevated IOP (RR 3.64, 95% CI 2.71 to 4.87), and need for medical (RR 3.04, 95% CI 2.36 to 3.91) or surgical interventions (RR 5.43, 95% CI 3.12 to 9.45). Intravenous tocilizumab 8 mg/kg/4 weeks achieved resolution of macular edema at 6 months in a higher proportion than subcutaneous tocilizumab 162 mg/week (OR 3.96; 95% CI 1.3-12.92; p=0.01), with no significant difference after 12 months (OR 2.46; CI 95% 0.30-30.18; p=0.40), gain in visual acuity after 12 months of 0.19 logMAR gain of BCVA in the intravenous group, inactive disease in 63% versus 58% (p=0.80), and treatment success in 71% of patients in both groups (p=0.99).

Brepocitinib's Uveitis Success: A New Standard for Ocular Inflammation

The recent positive Phase 3 results for brepocitinib in non-infectious uveitis represent a pivotal moment for patients grappling with this challenging inflammatory eye disease. The data, demonstrating a median of over 48 weeks to 'treatment failure' and an impressive 40 weeks without requiring immunosuppressive steroids, sets a new standard for disease management. This is particularly impactful given the significant burden of chronic corticosteroid use, which often leads to systemic side effects. The drug's ability to resolve macular edema, a primary driver of vision loss in uveitis, further underscores its potential to improve patient outcomes substantially.

This success reinforces the scientific rationale behind targeting the TYK2/JAK1 pathway, a mechanism implicated in various autoimmune conditions. Brepocitinib, already approved for dermatomyositis and showing promise in psoriatic arthritis and ulcerative colitis, is solidifying its position as a versatile therapeutic agent. For Priovant, this expands its market footprint and strengthens its competitive standing in the immunology sector, offering a differentiated oral option in a landscape currently populated by conventional immunosuppressants, anti-TNF-α agents, and IL-6 inhibitors.

However, the journey ahead is not without considerations. As a TYK2/JAK1 inhibitor, brepocitinib will face rigorous scrutiny regarding its long-term safety profile, particularly concerning class-specific adverse events such as infections and potential thromboembolic risks, which have been observed in other JAK inhibitor trials and in brepocitinib's IBD studies. The competitive landscape for non-infectious uveitis is robust, necessitating a clear differentiation strategy based on its unique efficacy and safety balance. Furthermore, while oral brepocitinib has shown broad efficacy, its topical formulation for mild-to-moderate psoriasis did not meet primary endpoints, highlighting the importance of precise indication targeting and formulation optimization. Ultimately, brepocitinib's potential to offer a new, steroid-sparing, and effective oral treatment for non-infectious uveitis could significantly reshape clinical practice, provided its long-term safety and real-world effectiveness align with these promising Phase 3 outcomes.